Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026)

Revolution Medicines' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 817.2% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 817.2% increase from a year earlier, with the FY2025 full-year figure at $18.5 million, up 2668.06% from the prior year.
• Other Non-Current Liabilities fell to $6.9 million in Q1 2026 per RVMD's latest filing, from $18.5 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $18.5 million in Q4 2025 and bottomed at $219000.0 in Q2 2022.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2023), against an average of $3.0 million.
• Biggest YoY gain for Other Non-Current Liabilities was 2668.06% in 2025; the steepest drop was 76.24% in 2025.
• Year by year, Other Non-Current Liabilities stood at $301000.0 in 2022, then surged by 384.39% to $1.5 million in 2023, then slumped by 54.05% to $670000.0 in 2024, then soared by 2668.06% to $18.5 million in 2025, then plunged by 62.91% to $6.9 million in 2026.
• Per Business Quant, the three latest RVMD Other Non-Current Liabilities figures stand at $6.9 million (Q1 2026), $18.5 million (Q4 2025), and $2.5 million (Q3 2025).